BR9808424A - Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto. - Google Patents

Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto.

Info

Publication number
BR9808424A
BR9808424A BR9808424-0A BR9808424A BR9808424A BR 9808424 A BR9808424 A BR 9808424A BR 9808424 A BR9808424 A BR 9808424A BR 9808424 A BR9808424 A BR 9808424A
Authority
BR
Brazil
Prior art keywords
preparation
compound
processes
pharmaceutical composition
intermediates
Prior art date
Application number
BR9808424-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Romano Di Fabio
Barbara Bertani
Giuseppe Alvaro
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of BR9808424A publication Critical patent/BR9808424A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9808424-0A 1997-03-26 1998-03-24 Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto. BR9808424A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9706294.7A GB9706294D0 (en) 1997-03-26 1997-03-26 Heterocyclic compound
PCT/EP1998/001700 WO1998042673A1 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist

Publications (1)

Publication Number Publication Date
BR9808424A true BR9808424A (pt) 2000-05-23

Family

ID=10809909

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808424-0A BR9808424A (pt) 1997-03-26 1998-03-24 Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto.

Country Status (20)

Country Link
EP (1) EP0971896A1 (xx)
JP (1) JP2001518901A (xx)
KR (1) KR20010005567A (xx)
CN (1) CN1257482A (xx)
AP (1) AP9901659A0 (xx)
AU (1) AU731394B2 (xx)
BR (1) BR9808424A (xx)
CA (1) CA2284710A1 (xx)
EA (1) EA199900755A1 (xx)
GB (1) GB9706294D0 (xx)
HU (1) HUP0001661A3 (xx)
ID (1) ID24306A (xx)
IL (1) IL131919A0 (xx)
IS (1) IS5186A (xx)
NO (1) NO994679L (xx)
NZ (1) NZ337793A (xx)
PL (1) PL335865A1 (xx)
TR (1) TR199902315T2 (xx)
WO (1) WO1998042673A1 (xx)
YU (1) YU47699A (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
DE10137487A1 (de) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
DE10306202A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
JP4360891B2 (ja) 2003-12-09 2009-11-11 アルパイン株式会社 放送受信機能を備えた電子装置およびその装置における電子番組ガイドの表示方法
US7910751B2 (en) * 2005-07-22 2011-03-22 Mochida Pharmaceutical Co., Ltd. Heterocyclidene acetamide derivative
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR102609676B1 (ko) 2017-06-12 2023-12-05 글리테크 엘엘씨. Nmda 길항제 및 d2/5ht2a 또는 선택적 5ht2a 길항제를 이용한 우울증의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
CA2232509A1 (en) * 1995-09-29 1997-04-10 Glaxo Wellcome Spa Tetrahydroquinolines as nmda antagonists
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds

Also Published As

Publication number Publication date
PL335865A1 (en) 2000-05-22
CA2284710A1 (en) 1998-10-01
IL131919A0 (en) 2001-03-19
EA199900755A1 (ru) 2000-08-28
WO1998042673A1 (en) 1998-10-01
NO994679D0 (no) 1999-09-24
HUP0001661A2 (hu) 2000-09-28
NO994679L (no) 1999-11-24
YU47699A (sh) 2001-12-26
AP9901659A0 (en) 1999-09-30
AU7209498A (en) 1998-10-20
KR20010005567A (ko) 2001-01-15
GB9706294D0 (en) 1997-05-14
AU731394B2 (en) 2001-03-29
NZ337793A (en) 2001-02-23
HUP0001661A3 (en) 2001-12-28
TR199902315T2 (xx) 2000-05-22
EP0971896A1 (en) 2000-01-19
JP2001518901A (ja) 2001-10-16
CN1257482A (zh) 2000-06-21
IS5186A (is) 1999-09-17
ID24306A (id) 2000-07-13

Similar Documents

Publication Publication Date Title
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
ES2133785T3 (es) Inhibidores de metaloproteinasas.
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
BR9713489A (pt) ácidos aminoalcanofosfÈnicos substituìdos
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
PT99445A (pt) Processo para preparacao de derivados do 1,4,7,10-tetraazaciclododecano mono-n--substituidos e de composicoes farmaceuticas que os contem
ATE61050T1 (de) Pyridazinamine wirksam gegen viren.
PT98710A (pt) Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem
BR9711098B1 (pt) compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
DE68913762D1 (de) Diarylverbindungen als antiatherosklerotische Mittel.
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DE3853910D1 (de) Molekulare köder und deren verwendung.
ATE83376T1 (de) Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten.
BR9808424A (pt) Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto.
ATE204177T1 (de) Verwendung von substanz p antagonist im pharmazeutischer zusammensetzung
BR9813514A (pt) Agente para tratamento de fibras queratìnicas
ES2104133T3 (es) Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico.
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A,8A E 9A

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1892 DE 10/04/2007.